Filing Details
- Accession Number:
- 0000899243-18-022697
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-08-17 16:05:36
- Reporting Period:
- 2018-08-15
- Accepted Time:
- 2018-08-17 16:05:36
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1113148 | Infinity Pharmaceuticals Inc. | INFI | Pharmaceutical Preparations (2834) | 330655706 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1697644 | Jeffery Kutok | C/O Infinity Pharmaceuticals, Inc. 784 Memorial Drive Cambridge MA 02139 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2018-08-15 | 8,180 | $2.01 | 6,133 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-08-16 | 6,133 | $2.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 9,542 | Indirect | 401(k) |
Footnotes
- The dispositions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2018.
- The price reported in this line of Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.00 to $2.0200, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.